Carisma, Guillerma .
HRN: 02-87-18 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/08/2025
CO-AMOXICLAV 625MG (TAB)
04/08/2025
04/15/2025
PO
625mg
Tid
Soft Tissue Swelling Sec. To Punctured Wound
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes